SECAUCUS, N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting ...

"Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient," said ...

Quest Diagnostics DGX recently launched its new laboratory blood test, AD-Detect Abeta, which combines 42/40 and p-tau217 Evaluation. It is designed to help physicians confirm amyloid brain pathology ...

Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health SECAUCUS, N.J ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

The new Quest test panel builds on prior AD-Detect tests that individually assess AB 42/40 and p-tau217, as well as p-tau181 and the ApoE isoform, a genetic risk marker. Those tests help providers ...